Product Description
Novavax vaccine candidate (Sourced from: https://www.takeda.com/newsroom/newsreleases/2021/takeda-to-manufacture-and-provide-150-million-doses-of-novavax-covid-19-vaccine-candidate-to-the-government-of-japan/)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Japan
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: COVID-19
Phase 2: Severe Acute Respiratory Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TAK-019-3001 | P3 |
Completed |
COVID-19 |
2022-06-11 |
|
| TAK-019-1501 | P2 |
Completed |
COVID-19|Severe Acute Respiratory Syndrome |
2022-03-28 |